Charles River Laboratories International, Inc. (CRL)
|Net Income (ttm)||443.35M|
|Day's Range||182.02 - 188.08|
|52-Week Range||182.02 - 455.60|
|Price Target||278.12 (+48.3%)|
|Earnings Date||Nov 1, 2022|
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provi... [Read more...]
In 2021, CRL's revenue was $3.54 billion, an increase of 21.08% compared to the previous year's $2.92 billion. Earnings were $390.98 million, an increase of 7.32%.Financial Statements
According to 20 analysts, the average rating for CRL stock is "Buy." The 12-month stock price forecast is 278.12, which is an increase of 48.32% from the latest price.
Charles River (CRL) continues to expect that the growth rate will approach 20% in the second half of 2022.
Charles River's (CRL) manufacturing collaboration with Cure AP-4 will support the latter's Phase I/II gene therapy trials for a rare neurodegenerative disorder.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories to Present at September Conferences
ALDERLEY PARK, England--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Cure AP-4 announce a manufacturing collaboration to provide HQ plasmid DNA for Phase I/II gene therapy trials against AP-4 ...
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces the addition of five CRADL locations, expanding operations to 27 vivarium facilities in key biohubs.
In Q2, the impact of foreign currency translation reduces Charles River's (CRL) reported revenue growth by 3.4%.
Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogene...
MEMPHIS, Tenn.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River is first CDMO in North America to receive EMA approval to commercially produce an allogeneic cell therapy drug product
Revenue decline in the CDMO business drag Charles River's (CRL) Manufacturing Solutions revenues down.
Charles River (CRL) delivered earnings and revenue surprises of 1.09% and 2.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories Announces Second-Quarter 2022 Results
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The broad-based demand and meaningful price increases in the RMS business, particularly in North America and China, are expected to have contributed to Charles River's (CRL) Q2 top line.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories Schedules Second-Quarter 2022 Earnings Release and Conference Call
Investors are optimistic about Charles River's (CRL) strong segmental growth and notable collaborations.
Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.
WILMINGTON, Mass. & MACCLESFIELD, England--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces the opening of their High Quality Plasmid DNA Centre of Excellence at Bruntwood SciTech's Alderley...
WILMINGTON, Mass. & GHENT, Belgium--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Ziphius Vaccines collaborate to deliver early-stage clinical supply of plasmid DNA for saRNA-based vaccine prog...
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.
Charles River and ASC Therapeutics to Scale Manufacturing of Second-Generation Gene Therapy for Hemophilia A
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and ASC Therapeutics announce expanded relationship to scale manufacturing for a second generation gene therapy for hemophilia A.
Charles River Laboratories International Inc. shares CRL, +0.89% slid 6% in premarket trade Wednesday, after the drug company issued a profit warning for the second quarter. The company is now expected ...
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #conference--Charles River Laboratories to present at June conferences